Synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-07. Numbers and descriptions here follow the published literature rather than marketing material.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
=== 1973 to 2009 === Hanmi was founded in 1973 by Lim Sung-ki, who was a pharmacist. It was originally named Lim, Sung-ki Pharmaceutical Co., but it was quickly changed to Hanmi Pharmaceutical. The company originally started selling Trimethoprim/sulfamethoxazole powder, and would expand to produce Cephalosporin antibiotics in 1985 and injectable Ceftriaxone antibiotics in 1987. By 1988 the company was listed in the Korea Exchange. Hanmi started selling drugs in China in 1996. In 1994, the company began developing Cyclosporin. The company broke the ₩100,000,000,000 barrier in sales in 1997. The company began moving into the European market in 1998. The company still was developing new drugs, with Paclitaxel in 2000, Itraconazole tablets in 2001, 24-hour controlled-release Nifedipine tablets and a new salt form of Amlodipine in 2004, and an anti-obesity drug using sibutramine mesilate in 2007. Hanmi and Crystal Genomics formed a strategic partnership in 2008.
Smoking earlier in life and smoking cigarettes with higher tar content increases the risk of these diseases. Additionally, other forms of environmental tobacco smoke exposure, known as passive smoke and third-hand smoke, have manifested harmful health effects in people of all ages. Tobacco use is also a significant risk factor in miscarriages among pregnant women who smoke. It contributes to several other health problems for the fetus, such as premature birth and low birth weight, and increases the chance of sudden infant death syndrome (SIDS) by 1.4 to 3 times. The incidence of erectile dysfunction is approximately 85 percent higher in men who smoke compared to men who do not smoke. Many countries have taken measures to control tobacco consumption by restricting its usage and sales. They have printed warning messages on packaging. Moreover, smoking bans in public places like workplaces, theaters, bars, and restaurants have been enacted to reduce exposure to passive smoke. Tobacco taxation inflating the price of tobacco products, have also been imposed. In the late 1700s and the 1800s, the idea that tobacco use caused certain diseases, including mouth cancers, was initially accepted by the medical community. In the 1880s, automation dramatically reduced the cost of cigarettes, cigarette companies greatly increased their marketing, and use expanded. From the 1890s onwards, associations of tobacco use with cancers and vascular disease were regularly reported.
== Preparation and use == Fruits can be dried whole (e.g., grapes, berries, apricot, plum), in halves, or as slices (e.g., mango, papaya, kiwi). Alternatively, they can be chopped after drying (e.g., dates), made into pastes, or concentrated juices. The residual moisture content can vary from small (3–8%) to substantial (16–18%), depending on the type of fruit. Fruits can also be spread out, dried and cut into strips in its puree form without the addition of sugar or fats with at least 50% moisture content as fruit leather, (see patent listed under the references section) or as a powder by spray or drum drying. They can be freeze dried. Fresh fruit is frozen and placed in a drying chamber under a vacuum. Heat is applied, and water evaporates from the fruit while it is still frozen. The fruit becomes very light and crispy and retains much of its original flavor. Dried fruit is widely used by the confectionery, baking, and sweets industries. Food manufacturing plants use dried fruits in various sauces, soups, marinades, garnishes, puddings, and food for infants and children. As ingredients in prepared food, dried fruit juices, purées, and pastes impart sensory and functional characteristics to recipes:
=== Relationship to land plants === Fossils of isolated spores suggest land plants may have been around as long as 475 million years ago (mya) during the Late Cambrian/Early Ordovician period, from sessile shallow freshwater charophyte algae much like Chara, which likely got stranded ashore when riverine/lacustrine water levels dropped during dry seasons. These charophyte algae probably already developed filamentous thalli and holdfasts that superficially resembled plant stems and roots, and probably had an isomorphic alternation of generations. They perhaps evolved some 850 mya and might even be as early as 1 Gya during the late phase of the Boring Billion.
== Function == Acting through melanocortin 1 receptor, α-MSH stimulates the production and release of melanin (a process referred to as melanogenesis) by melanocytes in skin and hair. Acting in the hypothalamus, α-MSH suppresses appetite. α-MSH secreted in the hypothalamus also contributes to sexual arousal.
Sources: en.wikipedia.org
Chymotrypsins (EC 3.4.21.1, including enzymes called alpha-chymotrypsin, chymotrypsin A, and chymotrypsin B) are digestive enzymes that form a component of pancreatic juice acting in the duodenum, where they perform proteolysis, the breakdown of proteins and polypeptides. In humans, the corresponding enzymes are encoded by the genes CTRB1 and CTRB2. The related enzyme chymotrypsin-C (EC 3.4.21.2) acts similarly, but with some differences including a preference for cutting leucine over phenylalanine bonds. Chymotrypsin preferentially cleaves peptide amide bonds where the side chain of the amino acid N-terminal to the scissile amide bond (the P1 position) is a large hydrophobic amino acid (tyrosine, tryptophan, and phenylalanine). These amino acids contain an aromatic ring in their side chain that fits into a hydrophobic pocket (the S1 position) of the enzyme. It is activated in the presence of trypsin. The hydrophobic and shape complementarity between the peptide substrate P1 side chain and the enzyme S1 binding cavity accounts for the substrate specificity of this enzyme. Chymotrypsin also hydrolyzes other amide bonds in peptides at slower rates, particularly those containing leucine at the P1 position. Structurally, it is the archetypal structure for its superfamily, the PA clan of proteases.
== Criticisms and controversies == In 1997, Dunkindonuts.org was established by a customer for disgruntled consumers and employees to lodge complaints about the company. The site appeared ahead of the company's own website in many search engines and received national media coverage before being purchased by Dunkin' Donuts in 1999. Dunkin' Donuts was criticized by one of its franchisees for allegedly forcing single-store owners to agree to a buyout at a loss for minor infractions. Dunkin' Donuts sued franchise owners 154 times from 2006 to April 2008. Over the same time span, McDonald's was involved in five lawsuits. Subway, a company that has four times the number of locations as Dunkin' Donuts, sued its franchisees 12 times. These figures do not include arbitrations, which the companies use in pursuing legal claims against their franchisees. Franchisees allege that the company's business strategy needs mainly multi-unit franchisees. In May 2010, Dunkin' Donuts was criticized for advertising "Free Iced Coffee Day" on its national Facebook page, which took place in only 13 cities. Due to the limited scope of the promotion, many customers became dissatisfied with the lack of free iced coffee and vented their anger on the Dunkin' Donuts Facebook page. In 2012, Dunkin' Donuts published its first formal Animal Welfare Policy, outlining its approach to humane sourcing and supplier standards. The company committed to eliminating gestation crates from its U.S.
== The hemocyanin superfamily == The arthropod hemocyanin superfamily is composed of phenoloxidases, hexamerins, pseudohemocyanins or cryptocyanins, and (dipteran) hexamerin receptors. Phenoloxidase are copper-containing tyrosinases. These proteins are involved in the process of sclerotization of arthropod cuticle, in wound healing, and humoral immune defense. Phenoloxidase is synthesized by zymogens and are activated by cleaving an N-terminal peptide. Hexamerins are storage proteins commonly found in insects. These proteins are synthesized by the larval fat body and are associated with molting cycles or nutritional conditions. Pseudohemocyanin and cryptocyanins genetic sequences are closely related to hemocyanins in crustaceans. These proteins have a similar structure and function, but lack the copper binding sites. The evolutionary changes within the phylogeny of the hemocyanin superfamily are closely related to the emergence of these different proteins in various species. The proteins within this superfamily would not be well understood without the extensive studies of hemocyanin in arthropods.
== Menu == Salad and Go used fresh natural ingredients. The menu offered eight salads with house-made dressings and a choice of proteins (chicken, steak and tofu). Every salad was available as a wrap. The menu also featured soup and five breakfast burrito options, also available to order as bowls.
As the confinement energy depends on the quantum dot's size, both absorption onset and fluorescence emission can be tuned by changing the size of the quantum dot during its synthesis. The larger the dot, the redder (lower-energy) its absorption onset and fluorescence spectrum. Conversely, smaller dots absorb and emit bluer (higher-energy) light. Recent articles suggest that the shape of the quantum dot may be a factor in the coloration as well, but as yet not enough information is available . Furthermore, it was shown that the lifetime of fluorescence is determined by the size of the quantum dot. Larger dots have more closely spaced energy levels in which the electron–hole pair can be trapped. Therefore, electron–hole pairs in larger dots live longer causing larger dots to show a longer lifetime. To improve fluorescence quantum yield, quantum dots can be made with shells of a larger bandgap semiconductor material around them. The improvement is suggested to be due to the reduced access of electron and hole to non-radiative surface recombination pathways in some cases, but also due to reduced Auger recombination in others.
Sources: en.wikipedia.org
When Dias was accused for the first time and much time after the beginning of the process, the journalist Hernâni Carvalho critiqued in many points the State's and police work:This only has the bad side of justice. It has the bad side of justice that didn't care about this for anything and it has the shameful side of justice that thirteen years later tries to fix it by hand (...) The Maddie [Madeleine McCann] case had governments, armies, firefighters, everyone looking for the [foreign] kid. This one was Portuguese and no one cared about him (...) We should be ashamed of what is happening. (...) When Rui Pedro went missing no one cared about anything and Afonso Dias, when the kid went missing said in front of many people (...) 'if you want to get the kid back close the borders'. They didn't do anything. And everything they did, was done poorly. (...) If today you know a lot, or a part of what happened it is because (...) the [journalist] Ana Leal did more for this that a lot of police officers that had that obligation. This is a shame. (...) The Portuguese State should already have taken care of this lady [Filomena Teixeira] that's suffering (...) just because they can't give her an answer, they didn't want to give her an answer. (...)
Apart from cost, patients and carriers of HBV infection are often confronted with tough conditions and social pressures, although such discrimination is illegal in China. Chinese drug regulation authorities have approved Swiss pharmaceutical firm Novartis AG's drug Sebivo, a brand name for telbivudine, as a treatment for chronic hepatitis B in February 2007. The decision comes shortly after Sebivo was recommended for approval in the European Union. The medicine was developed jointly by Novartis and U.S. biotech firm Idenix Pharmaceuticals Inc and has been shown in trials to produce significantly greater viral suppression compared to the commonly used treatment lamivudine. Sebivo won its first major approval in Switzerland in September 2006.
Lyon, Davor Solter and Azim Surani, for their pioneering work on epigenetic gene regulation in mammalian embryos 2005 Martin Chalfie and Roger Y. Tsien, for their pioneering development of powerful new tools that allow the direct visualization of molecules in living cells 2004 Andrew Z. Fire, Craig C. Mello, Victor Ambros and Gary Ruvkun, for their pioneering achievements in the discovery of gene silencing by double-stranded RNA 2003 Masakazu Konishi, Peter Marler and Fernando Nottebohm, for their pioneering achievements in the ethology and neurology of birdsong 2002 Ira Herskowitz, for his pioneering achievements in yeast genetics and cell biology 2001 Joan A. Steitz, for her work in establishing a sub-field of molecular biology concerning small nuclear ribonucleoproteins 2000 Peter B. Moore, Harry F. Noller, Jr. and Thomas A. Steitz, for their discovery that peptide bond formation on the ribosome is catalyzed exclusively by ribosomal RNA 1999 Roderick MacKinnon, for his research into the molecular foundations of electrical signal generation in neurons and other types of cells 1998 Elizabeth Blackburn and Carol Greider, for their outstanding work on the maintenance of telomeres 1997 H. Robert Horvitz and John E. Sulston, for their pioneering studies of cell lineage in the nematode worm 1996 Richard Axel, Linda B. Buck and A. James Hudspeth, for establishing the molecular basis of the senses of smell and hearing 1995 Thomas D. Pollard and James A. Spudich, for their fundamental contributions to our understanding of molecular motors 1994 Robert G.
The SADF believed that a covert sabotage operation was possible, as long as the destruction was not attributable to South Africa and a credible cover story could be used to link the attack to a domestic Angolan movement such as UNITA or the Front for the Liberation of the Enclave of Cabinda (FLEC). An attack on the oil platforms was ruled out, as this was beyond the capabilities of either UNITA or FLEC, so the SADF opted to infiltrate the refinery's oil storage facilities and mine the fuel tanks. The damage incurred would cripple Angola's ability to finance its military operations and give it greater economic incentive to accede to South African demands in the ongoing negotiations rather than risk returning to war. The sabotage mission received the code name Operation Argon, and 15 South African special forces operators deployed to Cabinda by sea in May 1985. They were discovered by a FAPLA patrol during the infiltration attempt, and two of the raiders were shot dead with a third, Captain Wynand Petrus du Toit, being captured. Under interrogation, du Toit confessed that the objective of Argon was to sabotage the storage tanks at Cabinda Gulf. The South African government disavowed du Toit and denied responsibility, but General Viljoen later confirmed the SADF's role in the operation. Consequently, the ceasefire imposed as a result of the Lusaka Accords collapsed, and further peace talks were abandoned. The diplomatic repercussions of Operation Argon's failure were immense.
Nausea: ~ 8%; 1% severe nausea and 1% discontinued treatment due to nausea. Diarrhea: ~ 7%; <1% of patients had severe diarrhea and <1% of patients discontinued treatment due to diarrhea. Less common adverse reactions: <1% A 2018 pooled analysis from three phase III, randomized, double-blind, placebo-controlled studies on usage for Opioid-Induced Constipation, found that the numbers of patients reporting adverse effects were similar in both the lubiprostone and placebo treatment groups for all opioid classes (P ≥ 0.125); however, gastrointestinal adverse effects were reported more frequently by those receiving lubiprostone than 2 of the 3 opioid groups. The most commonly reported TEAEs in the lubiprostone treatment groups were nausea (13.4%–18.1%), diarrhea (1.2%–13.9%), and abdominal pain (4.7%–5.6%). In the population overall, the greatest likelihood of experiencing the first episode of any of these three TEAEs was greatest in the first week of treatment and decreased thereafter. According to Medscape, the most common (>10%) were: Nausea, Diarrhea (7-12%), Headache (2-11%). Less common side effects (1-10%) included: Abdominal pain (4-8%), Abdominal distension (3-6%), Flatulence (4-6%), Vomiting (3%), Loose stools (3%), Edema (1-3%), Abdominal discomfort (1-3%), Dizziness (3%), Chest discomfort/pain (2%), Dyspnea (2%), Dyspepsia (2%), Fatigue (2%), Dry mouth (1%).
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.